OK Biotech Co., Ltd. (TPE:4155)
Taiwan
· Delayed Price · Currency is TWD 12.95
+0.05 (0.39%)
Apr 29, 2026, 1:30 PM CST
OK Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 1,556 | 1,670 | 1,192 | 1,484 | 1,263 | Upgrade
|
| Revenue Growth (YoY) | -6.81% | 40.11% | -19.65% | 17.42% | -14.89% | Upgrade
|
| Cost of Revenue | 1,127 | 1,394 | 995.1 | 1,139 | 1,077 | Upgrade
|
| Gross Profit | 429.25 | 275.66 | 196.88 | 344.96 | 186.83 | Upgrade
|
| Selling, General & Admin | 251.07 | 177.25 | 148.41 | 156.09 | 148.24 | Upgrade
|
| Research & Development | 59.04 | 57.93 | 46.71 | 48.73 | 28.74 | Upgrade
|
| Other Operating Expenses | - | -6.29 | -7.43 | 7.06 | -4.93 | Upgrade
|
| Operating Expenses | 321.36 | 218.44 | 208.95 | 243.15 | 178.74 | Upgrade
|
| Operating Income | 107.89 | 57.21 | -12.06 | 101.81 | 8.09 | Upgrade
|
| Interest Expense | -10.92 | -6.23 | -9 | -11.42 | -8.08 | Upgrade
|
| Interest & Investment Income | 3.42 | 6.1 | 7.15 | 4.43 | 1.3 | Upgrade
|
| Earnings From Equity Investments | 0.58 | 5.11 | 5.33 | 7.43 | 24.65 | Upgrade
|
| Currency Exchange Gain (Loss) | -18.83 | 49.28 | -9.86 | 59.91 | -9.19 | Upgrade
|
| Other Non Operating Income (Expenses) | 18.76 | 13.33 | 23.69 | 18.04 | 28.26 | Upgrade
|
| EBT Excluding Unusual Items | 100.9 | 124.8 | 5.24 | 180.2 | 45.03 | Upgrade
|
| Impairment of Goodwill | - | - | - | -6 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | 0.19 | Upgrade
|
| Gain (Loss) on Sale of Assets | 2.96 | 2.31 | 2.78 | 1.4 | 0.92 | Upgrade
|
| Pretax Income | 103.87 | 127.11 | 8.03 | 175.59 | 46.14 | Upgrade
|
| Income Tax Expense | 6.74 | 20.79 | 9.62 | 38.87 | 14.72 | Upgrade
|
| Earnings From Continuing Operations | 97.13 | 106.32 | -1.59 | 136.73 | 31.42 | Upgrade
|
| Minority Interest in Earnings | -14.68 | -12.34 | 4.54 | 6.74 | 12.04 | Upgrade
|
| Net Income | 82.45 | 93.98 | 2.95 | 143.46 | 43.46 | Upgrade
|
| Net Income to Common | 82.45 | 93.98 | 2.95 | 143.46 | 43.46 | Upgrade
|
| Net Income Growth | -12.26% | 3087.75% | -97.95% | 230.09% | -66.50% | Upgrade
|
| Shares Outstanding (Basic) | 142 | 143 | 128 | 105 | 104 | Upgrade
|
| Shares Outstanding (Diluted) | 146 | 146 | 128 | 130 | 118 | Upgrade
|
| Shares Change (YoY) | -0.35% | 14.02% | -1.41% | 9.95% | 18.84% | Upgrade
|
| EPS (Basic) | 0.58 | 0.66 | 0.02 | 1.37 | 0.42 | Upgrade
|
| EPS (Diluted) | 0.57 | 0.64 | 0.02 | 1.16 | 0.41 | Upgrade
|
| EPS Growth | -11.55% | 3119.04% | -98.28% | 182.57% | -68.83% | Upgrade
|
| Free Cash Flow | -90.28 | -310.79 | -426.74 | -46.31 | -57.16 | Upgrade
|
| Free Cash Flow Per Share | -0.62 | -2.12 | -3.32 | -0.36 | -0.48 | Upgrade
|
| Dividend Per Share | 0.300 | 0.300 | 0.300 | 1.115 | 0.907 | Upgrade
|
| Dividend Growth | - | - | -73.11% | 22.95% | -28.58% | Upgrade
|
| Gross Margin | 27.58% | 16.51% | 16.52% | 23.25% | 14.79% | Upgrade
|
| Operating Margin | 6.93% | 3.43% | -1.01% | 6.86% | 0.64% | Upgrade
|
| Profit Margin | 5.30% | 5.63% | 0.25% | 9.67% | 3.44% | Upgrade
|
| Free Cash Flow Margin | -5.80% | -18.61% | -35.80% | -3.12% | -4.52% | Upgrade
|
| EBITDA | 187.37 | 125.25 | 60.32 | 165.94 | 59.73 | Upgrade
|
| EBITDA Margin | 12.04% | 7.50% | 5.06% | 11.19% | 4.73% | Upgrade
|
| D&A For EBITDA | 79.48 | 68.04 | 72.38 | 64.13 | 51.64 | Upgrade
|
| EBIT | 107.89 | 57.21 | -12.06 | 101.81 | 8.09 | Upgrade
|
| EBIT Margin | 6.93% | 3.43% | -1.01% | 6.86% | 0.64% | Upgrade
|
| Effective Tax Rate | 6.49% | 16.36% | 119.86% | 22.13% | 31.90% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.